AbCellera Biologics Inc. - Ordinary Shares (ABCL) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2020 to Q4 2025

Type / Class
Equity / Ordinary Shares
Symbol
ABCL on Nasdaq
Shares outstanding
293,061,432
Price per share
$3.42
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
104,032,627
Total reported value
$524,646,193
% of total 13F portfolios
0%
Share change
-3,738,353
Value change
+$3,617,961
Number of holders
140
Price from insider filings
$3.42
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of AbCellera Biologics Inc. - Ordinary Shares (ABCL) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BAILLIE GIFFORD & CO 4.4% $30,947,287 12,894,703 BAILLIE GIFFORD & CO 30 Sep 2024

As of 30 Sep 2025, 140 institutional investors reported holding 104,032,627 shares of AbCellera Biologics Inc. - Ordinary Shares (ABCL). This represents 35% of the company’s total 293,061,432 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of AbCellera Biologics Inc. - Ordinary Shares (ABCL) together control 33% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BAKER BROS. ADVISORS LP 9.4% 27,525,640 0% 1% $138,453,969
Capital World Investors 4.6% 13,361,096 0% 0.01% $67,206,313
BAILLIE GIFFORD & CO 3.6% 10,422,966 +0.61% 0.04% $52,427,519
TWO SIGMA INVESTMENTS, LP 1.8% 5,175,142 +26% 0.04% $26,030,964
TWO SIGMA ADVISERS, LP 1.6% 4,799,900 +18% 0.05% $24,143,497
ArrowMark Colorado Holdings LLC 1.4% 4,105,095 0% 0.38% $20,648,628
BlackRock, Inc. 1.2% 3,641,779 -1.1% 0% $18,318,147
RENAISSANCE TECHNOLOGIES LLC 1.1% 3,360,729 +1.6% 0.02% $16,904,467
MORGAN STANLEY 0.95% 2,792,142 +180% 0% $14,044,475
TANG CAPITAL MANAGEMENT LLC 0.89% 2,600,000 0% 0.5% $13,078,000
UBS Group AG 0.85% 2,489,200 -28% 0% $12,520,677
MILLENNIUM MANAGEMENT LLC 0.83% 2,429,736 -28% 0.01% $12,221,572
BANK OF AMERICA CORP /DE/ 0.83% 2,418,304 +978% 0% $12,164,069
Guardian Partners Inc. 0.61% 1,786,414 0% 0.9% $10,647,027
Driehaus Capital Management LLC 0.59% 1,726,941 +245% 0.06% $8,686,513
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.48% 1,418,533 +139% 0.01% $7,135,221
CITADEL ADVISORS LLC 0.34% 1,008,615 -65% 0% $5,073,333
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 0.25% 736,945 0% $3,706,833
TUDOR INVESTMENT CORP ET AL 0.25% 730,122 0.02% $3,672,514
Jump Financial, LLC 0.23% 675,600 0.04% $3,398,268
STATE STREET CORP 0.23% 671,017 +9.2% 0% $3,375,216
DNB ASSET MANAGEMENT AS 0.22% 656,208 0.01% $3,300,726
LAZARD ASSET MANAGEMENT LLC 0.22% 652,096 +28% 0% $3,280,043
Intellectus Partners, LLC 0.19% 543,133 -0.91% 0.53% $2,731,958
ROYAL BANK OF CANADA 0.17% 503,964 +25% 0% $2,535,000

Institutional Holders of AbCellera Biologics Inc. - Ordinary Shares (ABCL) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 123,559 $422,636 -$93,490 $3.42 8
2025 Q3 104,032,627 $524,646,193 +$3,617,961 $5.03 140
2025 Q2 107,623,463 $370,594,083 -$42,109,102 $3.43 127
2025 Q1 124,693,841 $278,605,461 +$21,793,021 $2.23 127
2024 Q4 113,881,534 $333,794,803 +$26,551,987 $2.93 145
2024 Q3 104,704,785 $272,171,990 -$30,254,671 $2.60 138
2024 Q2 114,251,365 $337,827,363 -$10,256,153 $2.96 146
2024 Q1 119,954,877 $542,126,962 +$1,052,600 $4.53 152
2023 Q4 10,933,782 $62,445,535 -$153,628 $5.71 3
2023 Q3 119,035,181 $547,232,505 -$26,471,210 $4.60 135
2023 Q2 122,700,757 $795,296,987 -$50,606,062 $6.46 163
2023 Q1 130,004,988 $980,205,355 +$10,218,308 $7.54 180
2022 Q4 127,877,513 $1,296,042,864 +$62,055,224 $10.13 195
2022 Q3 117,122,782 $1,161,659,770 +$9,430,351 $9.89 179
2022 Q2 117,916,386 $1,256,997,535 +$149,188,256 $10.65 157
2022 Q1 113,059,720 $1,099,514,079 -$3,867,076 $9.75 123
2021 Q4 112,576,977 $1,600,469,412 +$96,069,936 $14.30 117
2021 Q3 96,887,382 $1,941,235,511 +$137,241,000 $20.04 112
2021 Q2 89,676,706 $1,966,718,250 +$162,743,337 $22.00 108
2021 Q1 70,619,849 $2,397,375,319 +$66,041,105 $33.96 82
2020 Q4 68,103,635 $2,740,470,000 +$2,587,817,902 $40.24 58